Tylocrebrine, formerly known as NSC-60387, is anticancer agent. In the 1960s, tylocrebrine entered phase I clinical trials as an anticancer drug candidate, but the trial was terminated due to its undesirable central nervous system side effects. References: Kirtane AR, Wong HL, Guru BR, Lis LG, Georg GI, Gurvich VJ, Panyam J. Reformulating Tylocrebrine in Epidermal Growth Factor Receptor Targeted Polymeric Nanoparticles Improves Its Therapeutic Index. Mol Pharm. 2015 Aug 3;12(8):2912-23. doi: 10.1021/acs.molpharmaceut.5b00173. PubMed PMID: 26065924; PubMed Central PMCID: PMC4525301.

纯度：≥98%

CAS：6879-02-3